[Prevention of recurrence with bismuth subsalicylate in a patient with recurrent and H2 receptor antagonist refractory duodenal ulcer].
Bayerdörffer
E
E
Medizinische Klinik II, Klinikum Grosshadern, Universität München.
Mannes
G A
GA
Pfaller
P
P
Sauerbruch
T
T
D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001729:Bismuth; D002927:Cimetidine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011899:Ranitidine / Q000008:administration & dosage*; D012008:Recurrence; D012459:Salicylates / Q000008:administration & dosage*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D002927:Cimetidine; D011899:Ranitidine; D001729:Bismuth
Rezidivprophylaxe mit Wismutsubsalizylat bei einem Patienten mit rezidivierendem und H2-Rezeptorantagonisten-resistentem Ulcus duodeni.